Newborn screening: What's new?

Research output: Contribution to journalArticle

Abstract

Screening newborn infants for inborn errors of metabolism (IEM) began in the United States almost 50 years ago with the introduction of testing for phenylketonuria (PKU) in the state of Maine. As the understanding of genetics and metabolism grew, and as testing methodologies became more automated and sensitive, both the number of states performing newborn screening (NBS) and the number of disorders for which patients can be screened began to grow. During the 1990s and the first decade of the 2000s, a new technology was introduced called tandem mass spectrometry (MS/MS) into the clinical laboratory and NBS arenas, which spurred the growth of screening to include as many as 30 disorders by almost all 50 states and Washington, DC. This technology gave laboratories the ability to rapidly and accurately test for multiple IEM simultaneously. Newborn screening programs became an integral part of assessing the health and well-being of every infant born in the United States.

Original languageEnglish (US)
Pages (from-to)737-741
Number of pages5
JournalLaboratory Medicine
Volume39
Issue number12
DOIs
StatePublished - 2008

Fingerprint

Inborn Errors Metabolism
Screening
Newborn Infant
Metabolism
Technology
Infant Welfare
Neonatal Screening
Phenylketonurias
Tandem Mass Spectrometry
Clinical laboratories
Testing
Health
Mass spectrometry
Growth

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Newborn screening : What's new? / Jones, Patricia M.

In: Laboratory Medicine, Vol. 39, No. 12, 2008, p. 737-741.

Research output: Contribution to journalArticle

Jones, Patricia M. / Newborn screening : What's new?. In: Laboratory Medicine. 2008 ; Vol. 39, No. 12. pp. 737-741.
@article{4e8703e620334b81a7fbe17f4d184cca,
title = "Newborn screening: What's new?",
abstract = "Screening newborn infants for inborn errors of metabolism (IEM) began in the United States almost 50 years ago with the introduction of testing for phenylketonuria (PKU) in the state of Maine. As the understanding of genetics and metabolism grew, and as testing methodologies became more automated and sensitive, both the number of states performing newborn screening (NBS) and the number of disorders for which patients can be screened began to grow. During the 1990s and the first decade of the 2000s, a new technology was introduced called tandem mass spectrometry (MS/MS) into the clinical laboratory and NBS arenas, which spurred the growth of screening to include as many as 30 disorders by almost all 50 states and Washington, DC. This technology gave laboratories the ability to rapidly and accurately test for multiple IEM simultaneously. Newborn screening programs became an integral part of assessing the health and well-being of every infant born in the United States.",
author = "Jones, {Patricia M.}",
year = "2008",
doi = "10.1309/LMOOXWVPSM5FC3B6",
language = "English (US)",
volume = "39",
pages = "737--741",
journal = "Laboratory Medicine",
issn = "0007-5027",
publisher = "American Society of Clinical Pathologists",
number = "12",

}

TY - JOUR

T1 - Newborn screening

T2 - What's new?

AU - Jones, Patricia M.

PY - 2008

Y1 - 2008

N2 - Screening newborn infants for inborn errors of metabolism (IEM) began in the United States almost 50 years ago with the introduction of testing for phenylketonuria (PKU) in the state of Maine. As the understanding of genetics and metabolism grew, and as testing methodologies became more automated and sensitive, both the number of states performing newborn screening (NBS) and the number of disorders for which patients can be screened began to grow. During the 1990s and the first decade of the 2000s, a new technology was introduced called tandem mass spectrometry (MS/MS) into the clinical laboratory and NBS arenas, which spurred the growth of screening to include as many as 30 disorders by almost all 50 states and Washington, DC. This technology gave laboratories the ability to rapidly and accurately test for multiple IEM simultaneously. Newborn screening programs became an integral part of assessing the health and well-being of every infant born in the United States.

AB - Screening newborn infants for inborn errors of metabolism (IEM) began in the United States almost 50 years ago with the introduction of testing for phenylketonuria (PKU) in the state of Maine. As the understanding of genetics and metabolism grew, and as testing methodologies became more automated and sensitive, both the number of states performing newborn screening (NBS) and the number of disorders for which patients can be screened began to grow. During the 1990s and the first decade of the 2000s, a new technology was introduced called tandem mass spectrometry (MS/MS) into the clinical laboratory and NBS arenas, which spurred the growth of screening to include as many as 30 disorders by almost all 50 states and Washington, DC. This technology gave laboratories the ability to rapidly and accurately test for multiple IEM simultaneously. Newborn screening programs became an integral part of assessing the health and well-being of every infant born in the United States.

UR - http://www.scopus.com/inward/record.url?scp=59849128155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59849128155&partnerID=8YFLogxK

U2 - 10.1309/LMOOXWVPSM5FC3B6

DO - 10.1309/LMOOXWVPSM5FC3B6

M3 - Article

AN - SCOPUS:59849128155

VL - 39

SP - 737

EP - 741

JO - Laboratory Medicine

JF - Laboratory Medicine

SN - 0007-5027

IS - 12

ER -